However, it's still too early to give any recommendations on what women should or shouldn't take during breast cancer treatment, says lead author Heather Greenlee, N.
CNN: Antioxidants may interfere with breast cancer treatment
Immunogen suffered a big setback in August when the FDA refused to even consider approving the new T-DM1 breast cancer drug its partner Roche is testing based on its technology.
In a study of 288 women from 2001, the drug tamoxifen reduced breast-cancer incidence among healthy BRCA2 carriers by 62% compared with a placebo, though it didn't reduce breast-cancer incidence among healthy women with BRCA1 mutations.
"This is just the tip of the iceberg as far as we're concerned, because it doesn't just apply to breast cancer, " says Amgen spokesman Michael Beckerich.
Indeed, there are a few of these on his list such as T-MD1 for breast cancer (Roche), alpharadin for prostate cancer (Bayer) and BG-12 for MS (Biogen-Idec).
Three studies of post-menopausal women show low- fat diets don't prevent heart disease, breast cancer, or colon cancer.
Because there's no reason we shouldn't be catching diseases like breast cancer and colon cancer before they get worse.
And insurance companies will be required to cover, with no extra charge, routine checkups and preventive care, like mammograms and colonoscopies -- because there's no reason we shouldn't be catching diseases like breast cancer and colon cancer before they get worse and cost more money.
That's because most women don't have BRCA1 and because most breast cancer is sporadic.
That's because most women don't have the mutation and because most breast cancer is sporadic.
This is something completely new about biology of breast cancer we didn't suspect.
Exemestane is licensed in the UK. However, at the moment it is only given to women with advanced breast cancer who won't benefit from surgery.
And perhaps most heartbreaking of all is the fact that right now, today in America, there are people in this country who have breast cancer but don't even know it, because they can't afford a mammogram.
"OK, scientists are still arguing about the dietary determinants of breast cancer and aren't too worried about fat, but they do worry about body weight, " the professor of nutrition, food studies and public health posted on her blog.
In the case of Avastin and Taxol, NICE says on its Web site it ended its appraisal of the combined drugs for metastatic breast cancer because it didn't receive a "full economic analysis" of the treatment from drugmaker Roche Products.
In breast cancer, the drug hasn't extended patients' lives at all in several studies.
Those who have survived breast cancer feel more research can't come soon enough, she said.
"I can tell my children that they don't need to fear they will lose me to breast cancer, " she said.
Reliable survival rates for breast cancer that has spread aren't available.
Women who took aspirin had a 13 percent lower risk of breast cancer than those who didn't, while those who took ibuprofen had a 21 percent lower risk.
Nearly 200, 000 women will learn they have breast cancer this year, and you don't want to be one of them.
Clinicians say leaving breast cancer untreated is a gamble they can't take.
Fran Visco, who is president of the National Breast Cancer Coalition, said researchers still don't have the answers, but at least they finally know the right questions.
This type of study can't prove conclusively that NSAIDs are responsible for the lower risk of breast cancer.
"These therapies aren't for everyone for now because it depends on how a woman perceives her risk of developing breast cancer, " Chlebowski said.
CNN: Scientists confirm tamoxifen works but say it isn't for everyone
Therein lies Soon-Shiong's next scientific adventure: stopping cancer from spreading from, say, the breast, where it won't kill, to the brain, where it will.
FORBES: Patrick Soon-Shiong and one of cancer's biggest riddles.
Results from another Women's Health Initiative (WHI) study showed a modest decrease in breast cancer risk in women who used calcium when compared with women who didn't use calcium.
CNN: Falling breast cancer rates: What's behind the numbers?
"These are among the most significant findings in drugs for metastatic cancer in the past five years, " said Eric Winer, director of the breast oncology center at Dana-Farber Cancer Institute in Boston, who wasn't directly involved in the trials.
应用推荐